Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women

Basit Öğe Kaydı
dc.contributor.authorEbinc, H.
dc.contributor.authorOzkurt, Z. N.
dc.contributor.authorEbin, F. A.
dc.contributor.authorUcardag, D.
dc.contributor.authorCaglayan, O.
dc.contributor.authorYilmaz, M.
dc.date.accessioned2020-06-25T17:48:03Z
dc.date.available2020-06-25T17:48:03Z
dc.date.issued2008
dc.description.abstractWe examined whether moxonidine influences lipid profile, insulin resistance, adiponectin levels, renal function and microalbuminuria in women with essential hypertension in a study of SS non-diabetic hypertensive patients and 53 normotensive women. Hypertensive patients received moxonidine for 12 weeks. At baseline the hypertensive group had significantly higher mean blood pressure, low-density lipoprotein cholesterol, triglycerides, total cholesterol, fasting glucose, urinary albumin excretion and homeostasis model assessment of insulin resistance (HOMA-IR), together with significantly lower mean high-density lipoprotein cholesterol, creatinine clearance and serum adiponectin than the normotensive group. Moxonidine significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR and albumin excretion, but significantly increased serum adiponectin. The change in adiponectin level was negatively correlated with the change in HOMA-IR. Moxonidine treatment may improve unfavourable metabolic status related to insulin resistance by increasing adiponectin levels in patients with essential hypertension. Since it can improve adiponectin levels, it may be used in the antihypertensive treatment of patients at high risk of diabetes and cardiovascular disease.en_US
dc.identifier.citationEbinç H, Ozkurt Z, Ebinç F, Ucardag D, Caglayan O, Yilmaz M. Effects of Sympatholytic Therapy with Moxonidine on Serum Adiponectin Levels in Hypertensive Women. Journal of International Medical Research. 2008;36(1):80-87.en_US
dc.identifier.doi10.1177/147323000803600111
dc.identifier.endpage87en_US
dc.identifier.issn0300-0605
dc.identifier.issn1473-2300
dc.identifier.issue1en_US
dc.identifier.pmid18230271
dc.identifier.scopus2-s2.0-39149097199
dc.identifier.scopusqualityQ2
dc.identifier.startpage80en_US
dc.identifier.urihttps://doi.org10.1177/147323000803600111
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4272
dc.identifier.volume36en_US
dc.identifier.wosWOS:000253171700011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of International Medical Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectmoxonidineen_US
dc.subjectimidazoline receptor agonistsen_US
dc.subjectessential hypertensionen_US
dc.subjectinsulin resistanceen_US
dc.subjectadiponectinen_US
dc.titleEffects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive womenen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.pdf
Boyut:
70.49 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu